NAD+

What Is NAD+? Structure, Role, and Why It Is Not a Peptide

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

NAD+ is nicotinamide adenine dinucleotide, a coenzyme present in every living cell at 663.4 Da. It is not a peptide: it contains no amino acids and no peptide bonds. It carries electrons in metabolic reactions and acts as a consumed substrate for several classes of enzyme.

Key facts

Full name
Nicotinamide adenine dinucleotide
Molecular weight
663.4 Da
Formula
C21H27N7O14P2
PubChem CID
5892
Chemical class
Dinucleotide coenzyme
Peptide?
No (no amino acids, no peptide bonds)
Present in
Every living cell

What it actually is

Two nucleotides joined tail to tail through a pyrophosphate bridge. One carries nicotinamide, the other adenine. That construction (sugar, base, phosphate, twice over) is nucleotide chemistry, the same chemistry that builds DNA and RNA. It has nothing structurally in common with a peptide.

The two jobs it does

First, electron carrier. NAD+ accepts a hydride to become NADH and passes it on, cycling between the two forms continuously without being consumed. This is the role in glycolysis and the citric acid cycle. Second, and quite differently, NAD+ is a substrate that gets used up: sirtuins, PARPs and CD38 all cleave it. That second role is why cellular levels can fall at all.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

Why the second role is the interesting one

A pure electron carrier would recycle indefinitely and its concentration would be a housekeeping detail. Because sirtuins and PARPs consume NAD+ as a substrate, demand from those enzymes draws down the pool, and the pool has to be resynthesised. That consumption is what connects NAD+ to DNA repair, to stress responses, and to the ageing literature that has grown up around it.

Why the field works with precursors

NAD+ is large and carries two negatively charged phosphate groups, which means it does not cross plasma membranes. Cells make their own from smaller precursors that do get in, namely nicotinamide riboside at 255.25 Da and nicotinamide mononucleotide at 334.22 Da. Almost all of the human trial literature uses those precursors rather than NAD+ itself, and that is a considered choice rather than an accident of availability.

What this means for a peptide catalogue

General peptide guidance does not apply here. There is no sequence, no purity-by-amino-acid-analysis, no disulfide chemistry, no protease susceptibility. The relevant chemistry is nucleotide chemistry (glycosidic and pyrophosphate bond hydrolysis), and the relevant literature is metabolic rather than peptide pharmacology.

Regulatory position

NAD+ holds no marketing authorisation as a medicine from the MHRA, EMA or FDA. Material supplied here is for laboratory research only, and no claim is made about ageing, energy or any condition in any person.

Frequently asked questions

Is NAD+ a peptide?

No. It is a dinucleotide coenzyme built from nucleotide chemistry, with no amino acids and no peptide bonds.

What does NAD+ do?

Two things: carries electrons in metabolism by cycling to NADH, and acts as a consumed substrate for sirtuins, PARPs and CD38.

Why do studies use NR and NMN instead?

NAD+ is too large and too charged to cross plasma membranes. Its smaller precursors do, so cells can build NAD+ from them internally.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.